Michael Macklin

Dr. Michael Macklin

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MMMichael Macklin
Michael Macklin
SYSudeep Yadav
Sudeep Yadav
RJReem Jan
Reem Jan
PRPankti D Reid
Pankti D Reid
Immune checkpoint inhibitors (ICI) are the standard of care for various malignancies and have been associated with a wide spectrum of complications that are phenotypically akin to primary autoimmune diseases. While the literature on these toxicities is growing, there is a paucity of data regarding ICI-associated scleroderma which can carry significant morbidity and limit the ability to continue effective ICI therapy. Our review aimed to analyze the current literature on ICI-associated systemic scleroderma (ICI-SSc) and key scleroderma mimics. Cases of ICI-SSc had notable differences from primary SSc, such as fewer vascular features and less seropositivity (such as scleroderma-specific antibodies and antinuclear antibodies). We found that patients with a diagnosis of SSc prior to the start of ICI can also experience flares of pre-existing disease after ICI treatment used for their cancer. Regarding scleroderma mimics, several cases of ICI-eosinophilic fasciitis have also been described with variable clinical presentations and courses. We found no cases of scleroderma mimics: ICI-scleromyxedema or ICI-scleroedema. There is a critical need for multi-institutional efforts to collaborate on developing a patient database and conducting robust, prospective research on ICI-scleroderma. This will ultimately facilitate more effective clinical evaluations and management for ICI-scleroderma.

5 September 2023 in Cells
Verified
Journal Article
Open access
PDF file
MMMichael Macklin
Michael Macklin
CTChelsea Thompson
Chelsea Thompson
LKLeticia Kawano-Dourado
Leticia Kawano-Dourado
IVIazsmin Bauer Ventura
Iazsmin Bauer Ventura
CWCamila Weschenfelder
Camila Weschenfelder
RTRobert Matthew Tighe
Robert Matthew Tighe
Adipose tissue has functions beyond its principal functions in energy storage, including endocrine and immune functions. When faced with a surplus of energy, the functions of adipose tissue expand by mechanisms that can be both adaptive and detrimental. These detrimental adipose tissue functions can alter normal hormonal signaling and promote local and systemic inflammation with wide-ranging consequences. Although the mechanisms by which adipose tissue triggers metabolic dysfunction and local inflammation have been well described, little is known about the relationship between adiposity and the pathogenesis of chronic lung conditions, such as interstitial lung disease (ILD). In this review, we detail the conditions and mechanisms by which adipose tissue becomes dysfunctional and relate this dysfunction to inflammatory changes observed in various forms of ILD. Finally, we review the existing basic and clinical science literature linking adiposity to ILD, highlighting the need for additional research on the mechanisms of adipocyte-mediated inflammation in ILD and its clinical implications.

10 June 2025 in JCR: Journal of Clinical Rheumatology
Verified
Journal Article
Closed access
MMMichael Macklin
Michael Macklin
IVIazsmin Md Bauer Ventura
Iazsmin Md Bauer Ventura
DKDinesh Md Khanna
Dinesh Md Khanna
Background: Options for systemic sclerosis–associated interstitial lung disease (SSc-ILD) have evolved rapidly. Mycophenolate mofetil (MMF) has replaced cyclophosphamide (CYC) in most cases of SSc-ILD, with the recent addition of tocilizumab (TCZ) in SSc-ILD as well. Combination immunosuppressive (CI) therapy with rituximab (RTX) and MMF, along with the antifibrotic nintedanib, have also become options. We aimed to better understand prescribing patterns and examine treatment trends overall to examine guideline penetrance. Methods: A survey polling international SSc experts was conducted from October 2023 through March 2024 by members of the Scleroderma Clinical Trials Consortium and the European Scleroderma Trials and Research Group. Results: MMF was the most common first-line treatment (92%) for SSc-ILD, followed by a split preference for RTX or TCZ for second/third line. Most experts add an antifibrotic (57%) or use CI therapy (24%) with failure of initial therapy. When CI therapy is used, MMF/RTX is used most (71%), followed by MMF/TCZ (38%). Corticosteroids were used for SSc-ILD treatment by 36% of experts, with 12% of these respondents using greater than 20 mg of prednisone equivalent. The survey response rate was 17.4% of total centers and 7.7% of total experts. Conclusion: First-line treatment preferences are in line with current treatment guidelines. CI therapy is not typically used, although the EVER-ILD trial might have influenced prescribing patterns with RTX/MMF CI therapy more typical. Prednisone use was more common than expected. Further studies evaluating combination MMF/TCZ versus MMF/RTX and whether TCZ is effective for SSc-ILD in patients without an inflammatory laboratory profile are necessary to help guide clinical practice. Further adoption of current guidelines may also change prednisone use patterns.

4 September 2024
Verified
Book Chapter
Closed access
PDF file
MMMichael Macklin
Michael Macklin
KTKimberly Trotter
Kimberly Trotter
Systemic lupus erythematosus (SLE) is a multisystem inflammatory autoimmune disease typically characterized by skin, joint, hematologic, and kidney involvement. The gastrointestinal manifestations are varied and often underrecognized by providers. SLE can additionally coexist with other gastrointestinal autoimmune disorders more commonly than in the general population. Specific manifestations of gastrointestinal disease in SLE may include intestinal pseudo-obstruction, esophageal motility, lupus peritonitis, lupus enteritis, protein-losing enteropathy, pancreatitis associated with SLE, lupus-associated acalculous cholecystitis, and lupus hepatitis. The severity of these conditions is highly variable and can mimic nonautoimmune gastrointestinal conditions, making their diagnosis challenging. This chapter serves as a dedicated review of gastrointestinal disease in SLE. <!----> <!----> <!----> <!---->

9 March 2022 in Journal of Advances in Medicine and Medical Research
Verified
Journal Article
Open access
PDF file
MMMichael Macklin
Michael Macklin
YZYousef Zarbalian
Yousef Zarbalian
LWLi Wang
Li Wang
RHRonald Hamilton
Ronald Hamilton
KLKimberly Liang
Kimberly Liang
Background and Objective: Transmural inflammation of the temporal artery on biopsy is considered strongly suggestive of giant cell arteritis (GCA). Occasionally other inflammation patterns are seen. It is controversial whether these findings predict GCA-like disease. Our objective was to describe the clinicopathologic features in a cohort of patients with temporal artery biopsies to examine outcomes of patients with non-transmural inflammation. Methods: We examined through retrospective chart review the clinical course from 2010-2020 of patients with temporal artery biopsies from 2010-2012. Biopsy results were divided into 3 groups: GCA transmural inflammation, non-GCA perivascular inflammation and negative. Non-GCA perivascular inflammation included small vessel, vasa vasorum and adventitial inflammation. Endpoints included constitutional and craniofacial symptoms, CRP and ESR levels, ASCVD, large vessel complications, and length of steroid treatment. Results: 95 patients were included. Transmural patients had more visual loss compared with perivascular patients (55.5% vs 15.7%, p=0.004). Transmural patients had more jaw claudication or headache/jaw claudication compared with perivascular patients (44.5% vs 12.6%, p=0.01). Weight loss was more common in transmural patients compared with perivascular (27.8% vs 3.1%, p=0.02). Night sweats, PMR symptoms, and temporal artery tenderness were similar between groups. CRP was higher in transmural patients though not significantly. ESR levels were similar between groups. Transmural patients had a longer steroid duration with a median of 24 months vs 1.5 for perivascular, p=0.001. Conclusion: Patients with non-transmural inflammation on temporal artery biopsies had improved outcomes when compared with transmural patients. This raises the question of whether steroids should be continued after a biopsy returns with perivascular inflammation.